Sermorelin, CJC-1295, and Tesamorelin are synthetic analogues of growth hormone-releasing hormone (GHRH). They share a common mechanism — GHRH receptor activation — but differ meaningfully in half-life, modification strategy, and research literature depth. Here is the comparison.
All three activate the GHRH receptor to stimulate pulsatile GH release from the anterior pituitary. Sermorelin is the shortest (29 amino acids, minutes of half-life). CJC-1295 extends half-life via DAC (Drug Affinity Complex) conjugation — with DAC: days; without DAC: ~30 minutes. Tesamorelin is the only GHRH analogue that received FDA approval in pharmaceutical form for a specific indication — the research-grade version has an extensive preclinical literature on visceral adiposity and body composition.
| Attribute | Sermorelin | CJC-1295 (with DAC) | Tesamorelin |
|---|---|---|---|
| Sequence length | 29 amino acids (GHRH 1-29) | 30 amino acids + DAC conjugate | 44 amino acids + stabilizing modifications |
| Preclinical half-life | Very short (~10 min) | Extended (~6-8 days) | Moderate (~30 min after modification) |
| GH release pattern | Pulsatile — preserves natural rhythm in preclinical models | Extended bleed — sustained elevation in models | Pulsatile — similar to natural pattern |
| Primary research focus | Age-related GH decline, pulsatile GH axis models | Sustained GH elevation models, body composition (often stacked with Ipamorelin) | Visceral adiposity, lipodystrophy-related fat redistribution, body composition |
| Modification strategy | Unmodified truncation of native GHRH | DAC (Drug Affinity Complex) — binds serum albumin | N-terminal trans-3-hexenoic acid modification |
| Typical dosing freq (research) | Daily, often evening | Weekly or 2x/week | Daily |
| SMART MD sizes | 5mg ($69.98), 10mg ($85.98) | 10mg ($72.98) · No-DAC 10mg ($69.98) | 5mg ($66.98), 10mg ($89.98) |
Sermorelin is the first 29 amino acids of endogenous GHRH — the minimum fragment needed to activate the GHRH receptor. Its very short half-life (~10 minutes in preclinical models) means it produces a single pulse of GH release that rapidly clears. This makes it valuable for researching pulsatile GH dynamics without introducing sustained elevation.
CJC-1295 exists in two forms: with DAC (Drug Affinity Complex) conjugation and without. With-DAC CJC-1295 covalently binds albumin via a maleimide linker, producing an extended preclinical half-life of approximately 6-8 days. Without DAC, CJC-1295 has a half-life similar to modified GHRH (~30 minutes). The no-DAC variant is often called "Mod GRF 1-29."
Extended half-life (~days). Produces sustained GH elevation rather than a pulsatile pattern. Used in research contexts where chronic GH axis elevation is the study question.
Short half-life (~30 min). Preserves pulsatile GH release. Commonly stacked with Ipamorelin (selective GHSR agonist) in research protocols studying combined GHRH + GHS pathway activation.
The CJC-1295 (no DAC) + Ipamorelin combination is one of the most-studied GHRH + GHS pathway protocols. SMART MD offers the pre-dosed 2X Blend CJC-1295 No DAC (5mg) / Ipamorelin (5mg) at $67.98 for this stack.
Tesamorelin is a 44-amino-acid GHRH analogue modified with a trans-3-hexenoic acid group at the N-terminus to enhance stability. It is the only GHRH analogue to have received FDA approval in pharmaceutical form for a specific indication (HIV-associated lipodystrophy). The research-grade version has an extensive preclinical literature base specifically in visceral adiposity and body composition models.
Choose Sermorelin or CJC-1295 no-DAC. Both preserve natural pulsatile GH rhythm. Sermorelin has deeper historical literature; no-DAC CJC-1295 is the more common modern choice in stacks.
Choose CJC-1295 with DAC. Its albumin-bound extended half-life produces days of elevated GH signal — useful for studying chronic GH axis effects in research models.
Choose Tesamorelin. It has the deepest preclinical literature on visceral fat reduction and body composition specifically. Commonly paired with Ipamorelin in blended research protocols.
Consult the primary literature. Older studies more often used Sermorelin; modern stacks more often use CJC-1295 no-DAC + Ipamorelin; adiposity-focused work tends toward Tesamorelin.
CJC-1295 with DAC (Drug Affinity Complex) has the longest half-life at approximately 6-8 days in preclinical models. This is achieved by covalent binding to serum albumin via a maleimide linker. Sermorelin is the shortest (~10 minutes), and Tesamorelin has an intermediate half-life (~30 minutes after N-terminal modification).
With DAC: covalent albumin binding extends half-life to ~6-8 days, producing sustained GH elevation. Without DAC (also called "Mod GRF 1-29"): short ~30-minute half-life, preserves pulsatile GH release. The no-DAC variant is more commonly used in stacks with Ipamorelin to replicate natural pulsatile GH rhythm.
Tesamorelin has the deepest preclinical literature specifically on visceral adiposity (trunk fat) and body composition models among GHRH analogues. Its pharmaceutical development pathway produced well-characterized pharmacokinetic data, and 40+ peer-reviewed preclinical studies have examined its effects on visceral fat reduction, lipodystrophy-related fat redistribution, and metabolic signaling.
Yes — GHRH + GHS (growth hormone secretagogue) dual pathway activation is one of the most-studied peptide stack protocols. GHRH analogues bind the GHRH receptor; Ipamorelin is a selective agonist of the GHS-R (ghrelin receptor). The combination produces synergistic GH release in preclinical models. SMART MD offers pre-dosed blends: CJC-1295 no-DAC + Ipamorelin, Tesamorelin + Ipamorelin (5mg or 10mg Tesa variants), and a 3X/4X blend with additional peptides.
Yes. Sermorelin, CJC-1295 (both variants), and Tesamorelin are legal to acquire for research purposes in the United States. They are classified as research-use-only compounds — not intended for human consumption in this form. Licensed researchers and physicians may acquire them for preclinical research protocols and practice-of-medicine use.
Every batch is verified by three independent U.S. laboratories. HPLC analysis (99%+ average purity), mass spectrometry for molecular weight confirmation, and LAL endotoxin assay (<5 EU/mg) are documented on a lot-specific Certificate of Analysis. Any batch can be verified before purchase at smartmdpeptides.com/verify.
Compare our COA to any other supplier's. The documentation is what separates verified research-grade from everything else.